Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT06009328 Recruiting - Overweight Children Clinical Trials

Fundamental Movement Skills, Body Mass Index and Quality of Life in Children

Start date: February 1, 2023
Phase:
Study type: Observational

Early childhood obesity is a serious worldwide problem, and fundamental movement skills (FMS) are very important factors in human movement. Thus, several advanced studies have examined the associations between FMS, body mass index (BMI) and quality of life. The purpose of this study was to investigate the relation between FMS, BMI and quality of life in Egyptian school aged children.

NCT ID: NCT06009276 Recruiting - Clinical trials for Overweight and Obesity

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

Start date: August 30, 2023
Phase:
Study type: Observational

The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle. This study is trying to find out if fitness status impacts the bacteria that are present in the oral microbiome (environment in the mouth) or the ability of the body to send blood to the skeletal muscle. Participants will complete all or some of the following: - A mouth swab to assess the bacteria in their mouths. - Produce a saliva sample into a tube. - Cycle on a bike until you reach maximum effort. - Undergo blood draws - Wear a 24-hour non-invasive device that monitors blood pressure. - Undergo a test to assess blood flow to the muscles measured with an ultrasound. - Drink 70mL (1/3 of a cup) of concentrated beetroot juice once

NCT ID: NCT06004843 Not yet recruiting - Hypoxia Clinical Trials

The Effects of Remimazolam on the Incidence of Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients

EROP
Start date: August 2023
Phase: N/A
Study type: Interventional

Hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. In sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. The present study is a single-center, randomized, single-blind, controlled clinical trial. Overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with ASA grade I or II, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. Sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of hypoxia during surgery between the two groups of patients.

NCT ID: NCT06002685 Recruiting - Inflammation Clinical Trials

Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention

Start date: October 9, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to evaluate the impacts of an attachment-based intervention (Attachment Biobehavioral Catch-Up (ABC) and Home Book-of-the-Week (HBOW) program on emerging health outcomes (i.e., common childhood illnesses, body mass index, and sleep) in low-income Latino children (N=260; 9 months at enrollment). It is hypothesized that children randomized to ABC will have better health outcomes in comparison to the HBOW control group.

NCT ID: NCT06001632 Recruiting - Clinical trials for Obesity Associated Disorder

Changes in Muscle Strength, Inflammatory Markers, and Body Composition in Response to Alternate Day Fasting Combined With Krill Oil Supplementation in Adults With Overweight and Obesity

Start date: March 28, 2022
Phase: N/A
Study type: Interventional

The goal of this double-blind, randomised, controlled trial is to determine the effects of LC n-3 PUFAs supplementation on changes in body composition and muscle strength during body weight loss and body weight maintenance among healthy adults living with overweight and obesity. The main research questions: - Is supplementation with LC n-3 PUFAs during dietary weight loss intervention (alternative-day fasting) attenuate the reduction in fat-free mass and muscle strength? - Is supplementation with LC n-3 PUFAs during dietary weight loss intervention (alternative-day fasting) provide additional impact on appetite related hormones (Acylated ghrelin, GLP-1, and PYY) and cardiometabolic risk factors (Post prandial inflammatory markers and Triglycerides)? Participants will be randomly assigned to a PLACEBO (Mix-vegetables oil) or LC n-3 PUFAs group (krill oil) (1:1 basis). Both groups will follow a dietary weight loss intervention (Alternate-day fasting). The study will last for 20 weeks that divided into 3 phases: four weeks of the preparation phase, eight weeks of body weight loss phase (Alternate Day Fasting), followed by eight weeks of body weight maintenance phase (regular diet).

NCT ID: NCT05997576 Not yet recruiting - Clinical trials for Overweight or Obesity

A Study of TG103 Injection in Non-diabetic Overweight or Obesity

Start date: September 1, 2023
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BMI greater than or equal to 28 kg/m2 or greater than 24 kg/m2 in the presence of comorbidities, in addition to lifestyle intervention (calorie restrict diet and increased physical activity).

NCT ID: NCT05996848 Recruiting - Clinical trials for Obesity or Overweight

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

REDEFINE 6
Start date: August 15, 2023
Phase: Phase 3
Study type: Interventional

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

NCT ID: NCT05995522 Completed - Clinical trials for Overweight and Obesity

Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare de effect of vitamin K2 in young adults with overweight or obesity. The main questions to answer are: What is the effect of Vitamin K2 supplementation on methylation, serum concentration of ucOC, cOC, Gas6, leptin, inflammatory markers, cardiometabolic risk factors, and cardiovascular risk in overweight or obese young adults? Participants will be assigned to one of two intervention groups where they will consume Vitamin K2 100 µg per day or cornstarch 500 mg per day for 90 days. If there is a comparison group: Investigators will compare the supplementation group (Vitamin K2) with the placebo group (cornstarch) to see if vitamin K2 supplementation modifies methylation, increases serum vitamin K, osteocalcin, growth arrest-specific 6 protein serum concentration, decreases serum leptin concentration, inflammatory markers and reduces cardiometabolic risk factors and cardiovascular risk.

NCT ID: NCT05987410 Recruiting - Clinical trials for Cardiovascular Diseases

EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Patients

VENERE
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Nordic Walking (NW) is a biomechanically correct walking technique that originated in Finland in the 1930s as an off-season training method for cross-country skiers. In the NW, the use of special sticks is combined with "conventional" walking: this involves a greater caloric expenditure, with an energy consumption higher by 20-30% compared to walking without sticks, and also toning of the upper part of the body, in particular triceps, shoulders and back, and the involvement of about 90% of the body's muscles, while maintaining a reduced load on ligaments and joints (Baek & Ha, 2021). The NW acts simultaneously and effectively on different components of fitness: coordination, endurance, strength, and mobility. It does not require sudden accelerations and is based on a technique that is easy to learn (with the help of an instructor), especially as regards maintaining correct posture. Finally, in addition to the cardiovascular benefits, NW has also been shown to effectively reduce the risk of falls in the elderly. The study is a single-center, randomized controlled trial (RCT), with a three-parallel-arm design, open-label. The primary objective is to evaluate the efficacy (in terms of cardiovascular performance), safety, and adherence (in terms of dropout rate) to the exercise prescription after 6 and 12 months follow-up of a 3-month NW intervention compared with standard rehabilitation training (SR, 3 months) in obese/overweight diabetic patients with cardiovascular (CV) complications. The study will enroll in parallel a control group that can access only generic cardiological counseling with a prescription for unsupervised home exercise.

NCT ID: NCT05987306 Recruiting - Clinical trials for Overweight and Obesity

A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss

Start date: September 24, 2023
Phase: N/A
Study type: Interventional

The goal of clinical trial is to test a novel weight loss approach combining a standard weight loss and internalized weight bias intervention with self-compassion exercises in overweight adults with moderate to high levels of internalized weight bias. The main question[s] it aims to answer are: 1) Can participants lose significant weight loss and 2) significantly reduce internalized weight bias. Participants will take part in a 12 week novel weight loss approach combining a standard weight loss and internalized weight bias intervention with self-compassion exercises using videoconferencing software.